fluoracizine has been researched along with nitrendipine in 1 studies
| Studies (fluoracizine) | Trials (fluoracizine) | Recent Studies (post-2010) (fluoracizine) | Studies (nitrendipine) | Trials (nitrendipine) | Recent Studies (post-2010) (nitrendipine) |
|---|---|---|---|---|---|
| 22 | 0 | 3 | 2,170 | 378 | 83 |
| Protein | Taxonomy | fluoracizine (IC50) | nitrendipine (IC50) |
|---|---|---|---|
| G-protein coupled receptor 55 | Homo sapiens (human) | 1.4652 | |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 0.0152 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.3 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Rattus norvegicus (Norway rat) | 0.0013 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Rattus norvegicus (Norway rat) | 0.0013 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 0.0152 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Rattus norvegicus (Norway rat) | 0.0013 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 10 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 0.0152 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 0.0152 | |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | 1.85 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruno-Blanch, L; Gálvez, J; García-Domenech, R | 1 |
1 other study(ies) available for fluoracizine and nitrendipine
| Article | Year |
|---|---|
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
Topics: Anticonvulsants; Computer Simulation; Databases, Factual; Discriminant Analysis; Drug Design; Molecular Structure; Quantitative Structure-Activity Relationship | 2003 |